For the Inventor, By the Inventor

Enter inventor name

Half Moon Bay, CA, United States of America

Bret Berner

USPTO Granted Patents = 65 (Patent Applications = 29)

CIPO Patents = 9 (Patent Applications = 4)

EPO Patents = 14 (Patent Applications = 21)

Average Co-Inventor Count = 3.3

ph-index = 24

Forward Citations = 8,363(Granted Patents)

Inventors with similar research interests:

Location History:

Scarsdale, NY (US) (1991 - 1999)
El Granada, US (2002)
El Granada, CA (US) (2000 - 2012)
San Carlos, CA (US) (2015)
Seattle, WA (US) (2020 - 2023)
Half Moon Bay, CA (US) (2009 - 2024)

Company Filing History:

Teikoku Pharma Usa, Inc.

4. 4 out of 6,850

Ciba-geigy Corporation

Sage Therapeutics, Inc.

Animas Corporation

Animas Technologies, LLC

8. 2 out of 166

Novartis Corporation

Immunogenics LLC

Alvine Pharmaceuticals, Inc.

St IP Holding Ag

Evecxia Therapeutics, Inc.

13. 2 out of 832,680

Other

patents

Years Active: 1991-2025

Loading Chart...

Loading Chart...

Loading Chart...

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12364692 - Topical naloxone compositions and methods for using the same (2025-07-22),

2. 12358942 - Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid (2025-07-15),

3. 11884696 - Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid (2024-01-30),

4. 11752107 - 5-hydroxytryptophan gastroretentive dosage forms (2023-09-12),

5. 11426403 - Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same (2022-08-30),

6. 11236121 - Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid (2022-02-01),

7. 11185544 - Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-l,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same (2021-11-30),

8. 10987342 - Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine (2021-04-27),

9. 10874642 - Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions (2020-12-29),

10. 10772871 - Dexmedetomidine transdermal delivery devices and methods for using the same (2020-09-15),

11. 10617655 - Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same (2020-04-14),

12. 10434150 - Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance (2019-10-08),

13. 10188616 - Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same (2019-01-29),

14. 10022340 - Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same (2018-07-17),

15. 9993531 - Formulation for oral administration of proteins (2018-06-12),

Title: Bret Berner: Innovator in Pharmaceutical Patents

Introduction

Bret Berner is a notable inventor based in Half Moon Bay, California. With an impressive portfolio of 62 patents, he has significantly contributed to the field of pharmaceutical innovations. His work focuses on developing novel compounds and formulations that enhance therapeutic efficacy.

Latest Patents

Among Bret's latest patents is the "Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid." This invention relates to a crystalline compound characterized by its unique formula, along with methods for producing and utilizing such formulations. Additionally, he has developed formulations of "4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione," detailing methods for creating these compositions and their therapeutic applications involving oltipraz crystals.

Career Highlights

Bret has amassed valuable experience through his work with leading companies in the pharmaceutical industry. Notable organizations where he has contributed include Depomed, Inc. and Cygnus, Inc. His dedication to innovation in drug formulation has led to new approaches in treatment strategies.

Collaborations

Collaborating with talented professionals has also played a significant role in Bret's achievements. He has worked alongside colleagues such as Gloria Gusler and Sui Yuen Eddie Hou, further fostering an environment of innovation and creativity in their projects.

Conclusion

Bret Berner continues to make strides in the field of pharmaceutical inventions. His extensive knowledge and innovative ideas have led to numerous patents that shape the future of medicinal treatments. With an unwavering commitment to research and development, Bret's contributions are set to leave a lasting impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…